We are live on ! Find out more
VTVT icon

vTv Therapeutics
VTVT

30 hedge funds and large institutions have $2.47M invested in vTv Therapeutics in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

11% more funds holding

Funds holding: 27 → 30 (+3)

0.01% more ownership

Funds ownership: 0.11% → 0.11% (+0.01%)

27% less capital invested

Capital invested by funds: $3.38M → $2.47M (-$919K)

50% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 8

Holders
30
Holders Change
+3
Holders Change %
+11.11%
% of All Funds
0.48%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
4
Reduced
8
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
V
Veritable
Delaware
+$184K
2
HSA
HBK Sorce Advisory
Pennsylvania
+$47.7K
3
DT
Diversified Trust
Tennessee
+$15.4K
4
HF
HRT Financial
New York
+$13.9K
5
Citadel Advisors
Citadel Advisors
Florida
+$13.1K

Top Sellers

Rank Fund Capital Flow
1
Prudential Financial
Prudential Financial
New Jersey
-$24.5K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$22K
3
VF
Virtu Financial
New York
-$17.7K
4
Millennium Management
Millennium Management
New York
-$10.9K
5
UBS Group
UBS Group
Switzerland
-$4.93K
Name Holding Trade Value Shares
Change 		Change in
Stake
SB
1
Samsara BioCapital
California
$1.08M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$623K +$562 +17 +0.1%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$188K -$529 -16 -0.2%
V
4
Veritable
Delaware
$161K +$184K +5,550 +1,061%
State Street
5
State Street
Massachusetts
$87.9K – – –
Millennium Management
6
Millennium Management
New York
$42K -$10.9K -331 -17%
HSA
7
HBK Sorce Advisory
Pennsylvania
$38K +$47.7K +1,442 New
BlackRock
8
BlackRock
New York
$36.6K -$165 -5 -0.4%
Citadel Advisors
9
Citadel Advisors
Florida
$31.9K +$13.1K +397 +48%
Northern Trust
10
Northern Trust
Illinois
$26.9K – – –
TSS
11
Two Sigma Securities
New York
$25.2K +$4.66K +141 +17%
Morgan Stanley
12
Morgan Stanley
New York
$22.2K – – –
SQA
13
Simon Quick Advisors
New Jersey
$19.6K – – –
BCM
14
Bridgeway Capital Management
Texas
$17.6K – – –
VF
15
Virtu Financial
New York
$15K -$17.7K -534 -49%
DT
16
Diversified Trust
Tennessee
$12K +$15.4K +466 New
HF
17
HRT Financial
New York
$10K +$13.9K +420 New
Prudential Financial
18
Prudential Financial
New Jersey
$6.79K -$24.5K -740 -74%
UBS Group
19
UBS Group
Switzerland
$5.14K -$4.93K -149 -43%
SFCL
20
Strengthening Families & Communities LLC
Massachusetts
$5K – – –
FWM
21
Focused Wealth Management
New York
$3.31K – – –
Osaic Holdings
22
Osaic Holdings
Arizona
$1K – – –
PA
23
Parallel Advisors
California
$979 – – –
Wells Fargo
24
Wells Fargo
California
$806 -$827 -25 -45%
CPG
25
Cornerstone Planning Group
New Jersey
$740 +$628 +19 New
1
2

VTVT Hedge Fund Activity: Q4 2022 in Review

30 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q4 2022, worth a combined $2.47M — down 27% from $3.38M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new VTVT positions and 3 closed out — a net gain of 3 holders — while 4 added to existing stakes and 8 trimmed.

The largest buyer was Veritable, adding an estimated $184K. The largest seller was Prudential Financial, cutting an estimated $24.5K.

  • 30 institutional investors held vTv Therapeutics (VTVT) as of Q4 2022, up from 27 in Q3 2022.
  • Funds reported $2.47M of vTv Therapeutics stock for Q4 2022, down 27% quarter-over-quarter.
  • 6 funds opened new vTv Therapeutics positions in Q4 2022 and 3 closed out, a net change of +3 holders.
  • The largest vTv Therapeutics buyer in Q4 2022 was Veritable, an estimated $184K added.
  • The largest vTv Therapeutics seller in Q4 2022 was Prudential Financial, an estimated $24.5K sold.

Based on aggregated 13F filings for Q4 2022.